Clinical Trial: Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035990) titled 'Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.' on June 04.

Brief Summary: The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Cystic Fibrosis (CF)

Intervention: DRUG: SION-451

* Pharmaceutical form: tablet

* Route of administration: oral

DRUG: SION-2222

* Pharmaceut...